A Landmark trial in East and Southern Africa finds injectable PrEP safe and effective for cisgender women
Regulatory review and introduction plans must be accelerated New York City, November 9, 2020— AVAC enthusiastically welcomes the news that another trial of the long-acting, injectable antiretroviral cabotegravir (CAB-LA) for HIV prevention for HIV pre-exposure prophylaxis (PrEP) has demonstrated safety and efficacy, this time among cisgender women. Today’s announcement from ViiV, the US National Institute of Allergy and…